Please assess the completion status of the following clinical trial:

Trial Title: Crisaborole Ointment 2% Skin Biomarker Biopsy Study in Atopic Dermatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of active atopic dermatitis (AD) with at least 6 month history prior to Screening and that has been clinically stable for 1 month.~* Investigator's Static Global Assessment (ISGA) of 2 (mild) or 3 (moderate) at Baseline.~* Body surface area (BSA) covered with AD of at least 0.5% and no more than 10% at Baseline, calculation excluding face, scalp, axilla, genitals, groin area, palms, back of the hands, and soles.~* Two lesions of AD at least 3 cm x 3 cm in size and at least 5 cm apart, with identical Lesion ISGA score of greater than/equal to 3.~Exclusion Criteria:~* Clinically infected AD or requires high potency topical corticosteroids or systemic (oral/injectable) corticosteroids to manage AD.~* History of angioedema or anaphylaxis to topical products or known sensitivity to components of crisaborole ointment 2%.~* History of cancer (except squamous or basal cell carcinoma or carcinoma in situ of the skin).~* Previous treatment with any topical or systemic PDE4 inhibitor unless stopped for the reason of lack of efficacy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Crisaborole ointment (Type: EXPERIMENTAL): None
- Placebo ointment (vehicle) (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).